BOM:524742

2 stories mentioning BOM:524742Updated 46d ago

Every FINWIRES story that references BOM:524742, newest first.

Caplin Point Laboratories' Consolidated Profit Rises in Fiscal Q4; Shares Jump 10%

Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742) consolidated attributable profit rose to 1.70 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.43 billion rupees a year ago.Earnings per share came in at 22.31 rupees from 18.69 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.Revenue from operations in fiscal Q4 also increased to 6.00 billion rupees from 5.02 billion rupees a year ago.The company's board declared an interim dividend of 4 rupees per equity share of face value of 2 rupees each for the financial year ended March 31.Caplin Point's shares were up over 10% in recent trade.

BOM:524742NSE:CAPLIPOINT

Asia55d ago

Caplin Point Laboratories Unit Gets US FDA's Final Nod for Calcium Gluconate Injection

Caplin Steriles, a subsidiary of Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742), has received final approval from the U.S. Food and Drug Administration (FDA) for its calcium gluconate injection, according to a Tuesday filing to the Indian stock exchanges.The drug is a generic therapeutic equivalent version of Fresenius Kabi's reference-listed drug.Calcium gluconate injection is indicated for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients.The company's shares were up nearly 2% in recent trade.

BOM:524742NSE:CAPLIPOINT

Track with the FINWIRES app suite

FolioX

Track BOM:524742 in your portfolio

WheelAI

Analyze BOM:524742 options with the wheel strategy

StockInsider

See market sentiment on BOM:524742